Cocrystal Pharma Reports Favorable Results from Single-Ascending Dose Cohorts of Phase 1 Study with CDI-988, its Oral Pan-Viral Norovirus/Coronavirus Protease Inhibitor #Cocrystal #COCP #Pharma #Viral #Norovirus #Coronavirus globenewswire.com/news-release/2…

Cocrystal Pharma Reports Second Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs #Cocrystal #COCP #Pharma #Antiviral globenewswire.com/news-release/2…

Cocrystal Pharma Advances Oral Pan-Viral Protease Inhibitor CDI-988 into Phase 1 Multiple-Ascending Dose Cohorts #Cocrystal #Pharma #COCP #Viral globenewswire.com/news-release/2…

Innovative Approaches to Antiviral Drug Development #Cocrystal #Pharma #COCP #Antiviral #DrugDevelopment xtalks.com/innovative-app…

Cocrystal Pharma’s Co-CEOs Highlight Pioneering Approach to Antiviral Drug Candidates Targeting Influenza and Coronaviruses as Fall Flu and COVID Season Begins globenewswire.com/news-release/2… #COCP #Cocrystal #Pharma #Influenza #Coronaviruses #COVID #Flu

Cocrystal Pharma - $COCP - Ep:019 - Nano Cap Podcast Jim Martin, CEO of Cocrystal Pharma, discusses leading a biotechnology company focused on developing antiviral treatments. Spotify: open.spotify.com/episode/3GOVWk… #COCP #Cocrystal #Pharma #Influenza #Coronaviruses #COVID #Flu

Cocrystal Pharma to Participate in a Fireside Chat at the Zacks SCR Life Sciences Virtual Investor Forum on March 13, 2025 nasdaq.com/press-release/… #COCP #Cocrystal #Nasdaq #pharma

On-Demand Webinar – Explore innovative antiviral therapeutics from $COCP at the Life Sciences Investor Forum, co-hosted by Zacks Small Cap Research. virtualinvestorconferences.com/wcc/eh/4814904… #COCP #Biotech #Pharma #Antiviral #Influenza #Norovirus #ClinicalTrials #PharmaInnovation

Learn how #COCP is advancing clinical programs for norovirus, influenza A, and coronaviruses with novel, direct-acting candidates designed to inhibit viral replication. Explore promising compounds CDI-988 and CC-42344, along with insights into future prospects.

Cocrystal Pharma’s Norovirus Oral Antiviral Candidate Demonstrates Potent Activity Against the Emerging GII.17 Variants cocrystalpharma.com/news/press-rel… #COCP #Cocrystal #Pharma #Norovirus

$COCP Cocrystal Pharma’s Norovirus Oral Antiviral Candidate Demonstrates Potent Activity Against the Emerging GII.17 Variants linkedin.com/feed/update/ur… #COCP #Cocrystal #Pharma #Antiviral #Norovirus

Cocrystal Pharma Reports First Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs #COCP #Cocrystal #Pharma #Antiviral #Drug #stocks globenewswire.com/news-release/2…

$COCP Cocrystal Pharma to Participate in Noble Capital Markets’ 2025 Emerging Growth Virtual Equity Conference #Cocrystal #Pharma #NobleCapital #COCP globenewswire.com/news-release/2…

$COCP Cocrystal Pharma’s Investigational Drug Candidate CC-42344 Demonstrates Strong Antiviral Potency Against the 2024 Highly Pathogenic H5N1 Avian Influenza Strain #COCP #Cocrystal #Pharma #Drug #Antiviral #Influenza globenewswire.com/news-release/2…

Cocrystal Pharma’s Novel Norovirus Antiviral to be Presented at Department of Defense Medical Conference #Cocrystal #Pharma #Norovirus #Antiviral globenewswire.com/news-release/2…

$COCP Cocrystal Pharma's CC-42344 shows 1,000x greater potency vs Tamiflu® against H5N1 avian flu strain · Targets highly pathogenic 2024 Texas strain · Novel PB2 inhibitor mechanism · Strong safety profile · Oral treatment candidate #COCP #H5N1 #InfluenzaResearch #Biotech

Cocrystal Pharma to present data from CDI-988 Phase 1 study at the 9th International Calicivirus Conference lnkd.in/dHMNaX4H

Cocrystal Pharma Receives FDA IND Clearance for Challenge Study of a Potential First Antiviral for Norovirus Prevention and Treatment ir.cocrystalpharma.com/press-releases…